Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma

Lorenzo Bello, Valeria Lucini, Francesco Costa, Mauro Pluderi, Carlo Giussani, Francesco Acerbi, Giorgio Carrabba, Marilou Pannacci, Dario Caronzolo, Silvia Grosso, Svetlana Shinkaruk, Federica Colleoni, Xavier Canron, Giustino Tomei, Gerard Deleris, Andreas Bikfalvi

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: We investigated the ability of the combinatorial administration of different inhibitors with activities on glioma angiogenesis, migration, and proliferation to produce a prolonged inhibition of glioma growth. Experimental Design: We combined inhibitors affecting solely tumor angiogenesis (PF-4/CTF, cyclo-VEGI) or inhibitors affecting both angiogenesis and invasion together (PEX, PF-4/DLR). Results: When administered in combination, these drugs produced a prolonged and increased inhibition of glioma growth independently from the type of inhibitor used. The combinatory administration was more effective than the administration of a single inhibitor alone, and a strong therapeutic response was reached with a significantly lower amount of protein. The strongest inhibition was observed when human PEX and PF-4/DLR, which affect both glioma angiogenesis and invasion by separate mechanisms, were combined. Conclusions: This supports the concept that prolonged glioma growth inhibition can be achieved by simultaneous delivery of molecules that target both tumor and endothelial cells and acting by separate mechanisms.

Original languageEnglish
Pages (from-to)4527-4537
Number of pages11
JournalClinical Cancer Research
Volume10
Issue number13
DOIs
Publication statusPublished - Jul 1 2004

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma'. Together they form a unique fingerprint.

Cite this